Attention

The medical device and therapy related information on this website is aimed exclusively at healthcare professionals.

The product related information on the websites covers – unless explicitly stated otherwise – only CE marked products which are marketable in the European Union. Please be aware that not all products and services described on the following website are cleared or available for sale in all countries. Please check the relevant country web site for details.

By clicking the button “Accepted and Confirmed” you assure that you have taken note of this information.

Back to Homepage Accepted and Confirmed

4008 series hemodialysis machines

DISCLAIMER

Not all products and services are cleared or available for sale in all EU countries. Check your country web site for details.

Container
Container

4008S*

The 4008S provides the following functionalities:

Online assessment of dialysis efficiency and dialysis dose with Online Clearance Monitor (OCM)
Ultrapure dialysis fluid with DIASAFEplus
Hygienic dry bicarbonate concentrate supply with bibag
Improved sustainability via dialysate, concentrate, water and energy savings with AdaptedFlow*
Integrated measurement of vital parameters with Blood Pressure Monitoring (BPM)
Optional data management with Therapy Data Management System (TDMS)
Intuitive and easy handling

*Feature is not available in all countries

Online assessment of dialysis efficiency and dialysis dose

Online Clearance Monitor (OCM*) enables the continuous monitoring of:

In-vivo urea clearance (K)
Accumulated cleared plasma (Kt) or the current administered dialysis dose (Kt/V)
Plasma sodium determination allows an adaptation of the sodium concentration of the dialysate to the physiological value of the patient. Sodium settings can be adapted during treatment* without incurring additional expenses for disposables or staff efforts

*OCM measurement is not possible in Single-Needle or ISO-UF mode

DIASAFEplus - The dialysis fluid filter

The quality and purity of the dialysis fluid are important and critical aspects to deliver high quality dialysis treatments and therefore of major concern in modern-day renal replacement therapies. Ultrapure dialysis fluid lowers the risk of bacterial contamination¹. The DIASAFEplus filter enables the production of ultrapure dialysis fluid in accordance with ISO standards^*. This is mainly attributed to the high endotoxin retention capabilities of its unique high quality inline steam sterilized Fresenius Polysulfone fibres¹¹.

* ISO 23500:2019: Preparation and quality management of fluids for hemodialysis and related therapies.

The advanced DIASAFEplus system enables:

Aseptic and reliable connection technology (DIAFIX lock system)
Functional control of filter integrity before and during treatment
Automatic surveillance of the filter´s lifetime

bibag - Online dry bicarbonate concentrate

Dry bicarbonate helps to prevent bacterial growth³
Easy and ergonomic handling via simple one-handed and hygienic connection to 4008S
Reduced required storage space compared to liquid bicarbonate in canisters
Improved sustainability due to reduced waste volume and less transport weight (compared to conventional concentrates)

Optional data management with Therapy Data Management System (TDMS)

Reduced effort in device setup by pre-setting of dialysis treatment parameters
Simplification of treatment documentation by continuously recording of dialysis treatment

Intuitive and easy handling

Ergonomic design and logical operating structure
Configurable Auto-On programs to start T1 test or a cleaning program
Optional connection to Central Delivery System (CDS) for acid concentrates

* The 4008S consists of the product 4008 S V10 and a software version equal or greater than 10.0

4008A

Reliable safety and handling features

Intuitive touch screen interface
Advanced patient monitoring
Low energy consumption - Operates at just 0.59 kW during treatment
Essential safety features
15-minute battery backup during power outage
Compact and smart design (dimensions & weight)
Production of ultrapure dialysis fluid with DIASAFEplus

Enables high-quality treatments – suggested medical benefits

Preservation of residual kidney function⁸ with ultrapure dialysis fluid¹⁰

Preservation of residual kidney function (RKF) is associated with lower all-cause mortality and higher quality of life⁹

RKF is the ability of native kidneys to eliminate water and uremic toxins in patients with end-stage kidney disease (ESKD)⁹
Preserving RKF is among the primary goals in managing patients with ESKD⁹
Ultrapure dialysis fluid as a standard in all treatments may contribute to the preservation of RKF¹⁰

Contact our local representative for more study results.

Reduction of inflammation with ultrapure dialysis fluid¹

Inflammation is associated with increased risk of mortality⁴

Contact our local representative for more study results.

Reduction of the risk of dialysis-related amyloidosis with ultrapure dialysis fluid⁶

Dialysis-related amyloidosis (DRA) is a serious complication of long-term hemodialysis⁷

DRA can lead to various bone and joint disorders, such as carpal tunnel syndrome and spondyloarthropathy⁷
It is characterized by the buildup and deposition of amyloid fibrils, mainly composed of β2 microglobulins (β2-m)⁷

Contact our local representative for more study results.

Contact our local representative for more product information by using the contact button.

1. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000;15:1207-1211.

2. Fresenius Medical Care. Unpublished internal data on file.

3. Ledebo I. and Ward R.A., Dialysis – History, Development and Promise, World Scientific Publishing (2012); Chapter 5N: 481-489.

4. Jofré R, Rodriguez-Benitez P, López-Gómez J, Pérez García R.. Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol 2006;17:274-280.

5. Lederer SR, Schiffl H. Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammation. Nephron 2002;91:452-455.

6. Furuya R et al. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients. Blood Purif 2005;23:311-316.

7. Scarpioni R et al. Dialysis-related amyloidosis: challenges and solutions. Int J Nephrol Renovasc Dis 2016;9:319-328.

8. Shafi T et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis 2010;56:348-358.

9. Liu X, Dai C. Advances in understanding and management of residual renalfunction in patients with chronic kidney disease. Kidney Dis 2017;2:187-196.

10. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002;17:1814-1818.

11 Canaud et al. Cellular interleukin-1 receptor antagonist production in patients receiving on-line haemodiafiltration therapy. Nephrol. Dial. Transplant.: 16, 2181-2187, 2001.

To top:

Attention

4008 series hemodialysis machines

DISCLAIMER